Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

BACKGROUND: The JACOB trial (NCT01774786) was a double-blinded, placebo-controlled, randomized, multicenter, international, phase III trial evaluating the efficacy and safety of adding pertuzumab to trastuzumab and chemotherapy in first-line treatment of human epidermal growth factor receptor 2 (HER...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Commun (Lond)
Main Authors: Liu, Tianshu, Qin, Yanru, Li, Jin, Xu, Ruihua, Xu, Jianming, Yang, Shujun, Qin, Shukui, Bai, Yuxian, Wu, Changping, Mao, Yixiang, Wu, Haiyan, Ge, Yilin, Shen, Lin
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6591878/
https://ncbi.nlm.nih.gov/pubmed/31234927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-019-0384-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados